Skip to main content

Beyond small molecules: A strategic guide to RNA, gene editing & next-gen therapeutics

Biochemistry tech abstract

Are you ready for the shift?
New therapeutic modalities—from RNA therapies to gene editing—are redefining the future of drug discovery. If you’re not adapting, you’re falling behind.

📈 By 2023, new modalities are set to account for 56% of total pipeline value. This white paper from Revvity Signals reveals how top pharma and biotech leaders are navigating this shift.

Inside, you'll learn:

  • Where multimodal innovation is heading next

  • How strategic partnerships (like Vertex + CRISPR) are breaking ground

  • What data strategies will set leaders apart

  • How to manage risk across complex R&D ecosystems

For R&D leaders, biotech founders, and pharma executives driving next-gen therapeutics.

Download the white paper now — and lead the change in drug discovery.

Download now

To access this content please enter your details in the fields below.
By submitting my personal data, I acknowledge that Revvity, Inc. and its affiliates ("Company") will process my personal data provided above consistent with the Revvity Signals Privacy Policy. I also agree to receive communications from Revvity Signals and understand that I can unsubscribe at any time.

Media Partners